Gossamer Bio (GOSS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Gossamer Bio has experienced numerous ups and downs over the years, including a clinical setback and significant staff reductions. Now, as it pursues potential approval for a heart drug, the company ...
As of April 8, 2026, sentiment around Gossamer Bio, Inc. (NASDAQ:GOSS) remains cautious, with 56% of covering analysts issuing "Hold" ratings on the stock. The consensus price target of $1 implies an ...
SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results